Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target Johnson & Johnson scores reversal of landmark $465M opioid ruling in Oklahoma Report ranks 10 most cost-efficient hospitals in the U.S., identifies $8B in potential Medicare savings Biogen's Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame? GE Healthcare to become standalone company after conglomerate completes three-way split GSK's ViiV turns to Black women's experiences in latest season of award-winning podcast Cue Health to kick off direct-to-consumer COVID test launch with new telehealth platform Health tech funding snapshot—Honor pulls in $370M; SoftBank's latest bets in healthcare Oak Street Health stock plummets with Q3 losses, DOJ inquiry Flagship unveils its next RNA bet with $50M for Alltrna to explore thousands of genetic diseases using transfer RNA Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability Mekonos closes Novartis-backed $25M series A for cell engineering platform Surgical device maker Arthrex fined $16M over alleged kickback scheme Featured Story | By Nick Paul Taylor Novartis has hacked off another piece of its $2.6 billion deal with Xencor, terminating its rights to a CD123xCD3 blood cancer bispecific that had a troubled time in early clinical development. read more |
| |
|---|
|
|
| Seven Keys to Success in Europe For emerging companies seeking to expand into Europe, there are many complexities and potential pitfalls. This 77-page e-book outlines the 7 keys to success when entering Europe for the first time. Download now. |
Top Stories By Eric Sagonowsky For years, Johnson & Johnson has been battling lawsuits alleging it played a role in creating the nationwide opioid epidemic. On Tuesday, just days after a high-profile trial win, the company scored major relief in appeals in a separate case. read more By Anastassia Gliadkovskaya A new ranking of the 10 most cost-efficient hospitals in the U.S. reveals that if all hospitals matched their performance, $8 billion could be saved in Medicare dollars. read more By Angus Liu Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a death reported to the FDA Adverse Event Reporting System (FAERS) will likely trigger more doubts around its use. read more By Andrea Park After years of speculation and false starts, General Electric is officially spinning off its healthcare business into an independent company. read more By Sharon Klahr Coey As with many diseases, Black women disproportionally bear the brunt of HIV. In 2019, 80% of new diagnoses were in going to women of color. GSK’s ViiV Healthcare tackles that disparity and more in season three of its award-winning podcast, “Being Seen.” read more By Conor Hale After being tapped by sports stadiums and professional athletes, Cue Health is now planning a nationwide, direct-to-consumer launch of its cartridge-based self-test this month, alongside a virtual health platform that will provide access to electronic prescription services and digital results that can help clear the user for travel. read more By Heather Landi Home and senior care platform Honor pulled in $370 million in new financing, Devoted Health notched a $1.15 billion funding round, Hinge Health clinched $400 million and other funding news from October. read more By Rebecca Torrence Oak Street Health's stock plunged 22% on Tuesday morning after the company posted deeper-than-expected third-quarter losses and revealed they face a potential investigation by the DOJ. The tech-enabled value-based primary care provider reported a loss of 49 cents per share in the third quarter of 2021 and also revealed in a filing that the DOJ has requested information related to whether the company had violated the False Claims Act. read more By Kyle LaHucik Flagship helped lead the way in messenger RNA by incubating Moderna. Now, the biotech founder wants to revolutionize transfer RNAs with $50 million dedicated to Flagship's newest venture, Alltrna. read more By Nick Paul Taylor Mirati Therapeutics is looking to a KRAS-Keytruda combination to give it an edge over Amgen in lung cancer. After lowering the dose of its KRAS drug, Mirati saw around 60% of first-line patients respond to the combination—and lessened the tolerability concerns that initially held back the cocktail. read more By Andrea Park The San Francisco-based company’s new funding will be used to help fine-tune the platform, which uses mechanical methods to deliver engineered DNA into cell therapies. read more By Andrea Park Arthrex agreed to a settlement with the U.S. Department of Justice over allegations that it paid an orthopedic surgeon to recommend and use its products, leading to improper requests for Medicare reimbursement. read more | 